WHO Holds Hydroxychloroquine Trial for COVID-19 Treatment

  • Posted on: 26 May 2020
  • By: sanyu-fm-news

The World Health Organisation has halted the use of Hydroxychloroquine in its solidarity drug trial after an observational study published in The Lancet found the drugs to be ineffective in treating the Coronavirus (COVID-19).

Hydroxychloroquine and Chloroquine were part of the four drugs being studied by the WHO in their solidarity trial taking place in over 17 countries. The other drugs were remedesvir and Lopinavir.

But according to the authors of the largest study on the drugs, published last week, it was discovered that patients who used Hydroxychloroquine alone or in a combination of an antibiotic had higher mortality rates and heart problems than those who were not.

Dr Tedros Adhanom Ghebreyesus, the WHO Director-General says that they have decided to halt the use of hydroxychloroquine arm of its solidarity global clinical trial as a review of evidence on the drugs takes place.

Dr Ghebreyesus, however, added that the two drugs can be used for autoimmune disease or malaria as the review takes place.

Uganda is still using Hydroxychloroquine to treat COVID-19 in its hospitals. According to Dr Diana Atwine, the drug has presented good results in patients that have used it.  So far, Uganda had a confirmed 222 COVID-19 patients. 69 of these have already been discharged after testing negative for the virus in subsequent tests.